Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 03:23 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Macitentan to Prevent PRVO
NCT05946811 · University of Maryland, Baltimore · PHASE3 · withdrawn · last registry update 2024-03-08 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Study was cancelled by funding agency before starting enrollment.” | – | Registry record, University of Maryland, Baltimore |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against EDNRB within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2025-02-20Also stopped (withdrawn): Franz Rischard, DO, Opsumit 10 Mg Tablet (NCT03726398)
- 2025-02-04Also stopped (terminated): Actelion, Inhaled Iloprost (5 μg) + Inhaled Placebo (NCT00302211)
- 2025-02-04Also stopped (terminated): Actelion, bosentan (NCT00313196)
- 2025-02-04Also stopped (terminated): Actelion, macitentan 10 mg (NCT03714815)
- 2025-02-04Also stopped (terminated): Actelion, Bosentan (NCT00310830)
- 2025-02-04Also stopped (terminated): Actelion, Bosentan + Matching placebo (NCT01389856)
- 2025-02-04Also stopped (terminated): Actelion, Macitentan 3 mg + Macitentan 10 mg (NCT01474122)
- 2025-02-03Also stopped (terminated): Actelion, a drug against EDNRB (NCT04955990)
- 2025-02-03Also stopped (terminated): Actelion, Bosentan (NCT00360087)
- 2024-11-12Results posted on the registry: University of Edinburgh, Isosorbide Mononitrate XL (ISMN) + Cilostazol (NCT03451591)
- 2024-11-01Results posted on the registry: United Therapeutics, Treprostinil Inhalation Powder (NCT03950739)
- 2024-10-15Also stopped (terminated): Duke University, Inhaled Iloprost (NCT02170519)
- 2024-08-23Results posted on the registry: Universitaire Ziekenhuizen KU Leuven, Antithrombin-III + Infliximab (NCT02251041)
- 2024-07-30Results posted on the registry: Liquidia Technologies, Inc., LIQ861 Inhaled Treprostinil (NCT03399604)
- 2024-05-29Phase 3 first posted: Radboud University Medical Center, Endothelin Receptor Antagonist (NCT06432452)
- 2024-03-12Results posted on the registry: University of California, Los Angeles, Macitentan (NCT05373108)
- 2024-03-05Results posted on the registry: United Therapeutics, IV Remodulin + Placebo (NCT02261883)
- 2024-03-05Also stopped (terminated): United Therapeutics, IV Remodulin + Placebo (NCT02261883)
- 2024-02-20Also stopped (withdrawn): University of Missouri-Columbia, Hyperinsulinemic, euglycemic infusion (NCT05518422)
- 2024-01-03Also stopped (terminated): United Therapeutics, treprostinil (NCT00439946)
- 2024-01-03Also stopped (terminated): United Therapeutics, treprostinil sodium (NCT00643604)
- 2023-12-19Also stopped (withdrawn): United Therapeutics, treprostinil sodium + Placebo (NCT01884038)
- 2023-11-13Results posted on the registry: Actelion, FDC macitentan/tadalafil + Macitentan 10 mg (NCT03904693)
- 2023-10-31Results posted on the registry: University of Mississippi Medical Center, Sildenafil 100 mg + Bosentan 125 mg (NCT04770155)
- 2023-10-31Also stopped (terminated): University of Mississippi Medical Center, Sildenafil 100 mg + Bosentan 125 mg (NCT04770155)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision